4.7 Article

Mutations in blaKPC-3 That Confer Ceftazidime-Avibactam Resistance Encode Novel KPC-3 Variants That Function as Extended-Spectrum β-Lactamases

Journal

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Volume 61, Issue 5, Pages -

Publisher

AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.02534-16

Keywords

KPC; ceftazidime-avibactam; drug resistance mechanisms; site-directed mutagenesis

Funding

  1. National Institutes of Health [UM1AI104681, R21AI288338, R21AI111037, K08AI114883]

Ask authors/readers for more resources

We identified four bla(KPC-3) mutations in ceftazidime-avibactam-resistant clinical Klebsiella pneumoniae isolates, corresponding to D179Y, T243M, D179Y/T243M, and EL165-166 KPC-3 variants. Using site-directed mutagenesis and transforming vectors into Escherichia coli, we conclusively demonstrated that mutant bla(KPC-3) encoded enzymes that functioned as extended-spectrum beta-lactamases; mutations directly conferred higher MICs of ceftazidime-avibactam and decreased the MICs of carbapenems and other beta-lactams. Impact was strongest for the D179Y mutant, highlighting the importance of the KPC Omega-loop.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available